NORWELL, MA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)NATIONAL ORGANIZATION FOR RARE DISORDERS INC, founded in 1983, is a mid-sized nonprofit that reported $34.6M in total revenue in fiscal year 2025. Revenue fell 32% from the prior year — a significant decline worth monitoring. Expenses of $40.4M exceeded revenue, resulting in a 17% operating deficit.
NORD STRIVES TO IMPROVE THE HEALTH AND WELL-BEING OF PEOPLE WITH RARE DISEASES BY DRIVING ADVANCES IN CARE, RESEARCH, AND POLICY.
NORD'S PATIENT ASSISTANCE PROGRAMS PROVIDE ELIGIBLE INDIVIDUALS WITH FINANCIAL ASSISTANCE TO SUPPORT THE BROAD RANGE OF CARE AND TREATMENT NEEDS ASSOCIATED WITH MANAGING A RARE DISEASE. EACH...
NORD'S PATIENT ASSISTANCE PROGRAMS PROVIDE ELIGIBLE INDIVIDUALS WITH FINANCIAL ASSISTANCE TO SUPPORT THE BROAD RANGE OF CARE AND TREATMENT NEEDS ASSOCIATED WITH MANAGING A RARE DISEASE. EACH DISEASE-SPECIFIC PROGRAM IS DESIGNED TO ADDRESS THE NUANCES OF THE INDIVIDUAL CONDITION AND THE UNIQUE NEEDS OF ITS PATIENT COMMUNITY. ASSISTANCE MAY INCLUDE SUPPORT FOR HEALTH INSURANCE PREMIUMS, COPAYMENTS, AND COINSURANCE, AS WELL AS CERTAIN COVERED OUT-OF-POCKET MEDICAL EXPENSES. NORD'S APPROACH ENSURES THAT ELIGIBLE INDIVIDUALS, WHETHER COMMERCIALLY INSURED, PUBLICLY INSURED, UNDERINSURED, OR UNINSURED, RECEIVE THE FINANCIAL SUPPORT NECESSARY TO ACCESS THE CARE AND TREATMENT PRESCRIBED BY THEIR HEALTH CARE PROVIDER(S). IN 2025, NORD'S PATIENT ASSISTANCE PROGRAMS PROVIDED FINANCIAL ASSISTANCE TO 6,880 INDIVIDUALS, INCLUDING 6,602 INDIVIDUALS SUPPORTED THROUGH OUR PAP AND 278 INDIVIDUALS WHO RECEIVED TRAVEL AND LODGING ASSISTANCE TO PARTICIPATE IN CLINICAL TRIALS.
NORD'S EDUCATIONAL INITIATIVES STRIVE TO EMPOWER PATIENTS AND THEIR FAMILIES, INFORM AND EDUCATE STUDENTS ACROSS DISCIPLINES FROM HIGH SCHOOL THROUGH GRADUATE SCHOOL, AND SUPPORT THE VITALLY...
NORD'S EDUCATIONAL INITIATIVES STRIVE TO EMPOWER PATIENTS AND THEIR FAMILIES, INFORM AND EDUCATE STUDENTS ACROSS DISCIPLINES FROM HIGH SCHOOL THROUGH GRADUATE SCHOOL, AND SUPPORT THE VITALLY IMPORTANT WORK OF PHYSICIANS AND OTHER HEALTHCARE PROFESSIONALS IN IMPROVING THE RECOGNITION OF SYMPTOMS OF RARE DISEASE AND EARLY, ACCURATE DIAGNOSIS AS WELL AS IMPROVING CLINICIAN KNOWLEDGE AND COMPETENCE IN TREATING RARE DISEASES. THIS IS DONE THROUGH THE DEVELOPMENT OF NORD'S RARE DISEASE DATABASE OF MORE THAN 1,480 COMPREHENSIVE EXPERT-WRITTEN REPORTS ON SPECIFIC RARE DISORDERS, THE DELIVERY OF RARE DISEASE VIDEOS AND WEBINARS, AND THROUGH ROBUST EDUCATIONAL PROGRAMMING WITH NORD'S CME PROGRAM AND AT THE NORD RARE DISEASES AND ORPHAN PRODUCTS BREAKTHROUGH SUMMIT. IN 2025, 759 PEOPLE ATTENDED THE NORD SUMMIT IN PERSON, AND 60 PEOPLE REGISTERED TO ATTEND VIRTUALLY. ALSO, IN 2025, THERE WERE OVER 15 MILLION VISITORS TO NORD'S RARE DISEASE DATABASE.
IN 2025, NORD CONTINUED TO ADVANCE THE IAMRARE NATURAL HISTORY AND REGISTRY PLATFORM TO STRENGTHEN RARE DISEASE RESEARCH AND IMPROVE THE PATIENT EXPERIENCE IN SUPPORT OF THERAPEUTIC DEVELOPMENT...
IN 2025, NORD CONTINUED TO ADVANCE THE IAMRARE NATURAL HISTORY AND REGISTRY PLATFORM TO STRENGTHEN RARE DISEASE RESEARCH AND IMPROVE THE PATIENT EXPERIENCE IN SUPPORT OF THERAPEUTIC DEVELOPMENT. MAJOR PLATFORM ENHANCEMENTS INCLUDED THE LAUNCH OF A REDESIGNED UI TO STREAMLINE NAVIGATION AND IMPROVE CROSS-BROWSER CONSISTENCY, AND THE RELEASE OF THE IAMRARE MOBILE APP WITH FEATURES SUCH AS PUSH NOTIFICATIONS FOR SURVEY REMINDERS AND DEVICE-LEVEL ACCESSIBILITY CONTROLS. AS OF DECEMBER 2025, THERE WERE 22,142 CONSENTED PARTICIPANTS ACROSS 51 REGISTRIES. IN ADDITION, DURING 2025, 10 NEW RARE DISEASE REGISTRIES WERE LAUNCHED, REPRESENTING THE LARGEST NUMBER INITIATED IN A SINGLE YEAR, AND THE RESEARCH TEAM WAS SUPPORTING THE DEVELOPMENT OF 24 ADDITIONAL REGISTRIES.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2025 | 2024 | Change | |
|---|---|---|---|
| Revenue | $34,577,196 | $50,676,798 | -0.3% |
| Expenses | $40,401,111 | $43,034,462 | -0.1% |
| Net Income | $-5,823,915 | $7,642,336 | -1.8% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| PAMELA GAVIN | CEO | 35.00 |
Officer
Director
|
$479,961 | $32,088 | $512,049 |
| KATHLEEN HOLCOMBE | CHAIR | 10.00 |
Officer
Director
|
$0 | $0 | $0 |
| DENNIS JACKMAN | VICE CHAIR | 5.00 |
Officer
Director
|
$0 | $0 | $0 |
| MARK SKINNER | TREASURER | 5.00 |
Officer
Director
|
$0 | $0 | $0 |
| LORNA WEIR | SECRETARY | 5.00 |
Officer
Director
|
$0 | $0 | $0 |
| KIM ISENBERG | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| PAUL LYONS | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| SUSAN BERRY MD | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| SHAFALI JESTE MD | DIRECTOR (UNTIL 12/2025) | 1.00 |
Director
|
$0 | $0 | $0 |
| PHILIP PEARL MD | DIRECTOR (UNTIL 12/2025) | 1.00 |
Director
|
$0 | $0 | $0 |
| MIKE PORATH | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| TOM KELLY | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| STEVEN MAH PHD | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| ALAN MILLER MD PHD | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| SHELDON SCHUSTER PHD | DIRECTOR | 1.00 |
Director
|
$0 | $0 | $0 |
| JIM PALMA | DIRECTOR (UNTIL 12/2025) | 1.00 |
Director
|
$0 | $0 | $0 |
| PETER SALTONSTALL | SENIOR ADVISOR & CEO EMERITUS | 17.00 |
Officer
|
$47,303 | $2,358 | $49,661 |
| NEETA KOTECHA | VP & CFO | 35.00 |
Officer
|
$186,375 | $38,387 | $224,762 |
| KELLEEN ESPERIAS | CHIEF STRATEGY & OPERATIONS OFFICER | 35.00 |
Officer
|
$294,239 | $29,613 | $323,852 |
| EDWARD NEILAN | CHIEF MEDICAL & SCIENTIFIC OFFICER | 35.00 |
Highest
|
$270,662 | $60,560 | $331,222 |
| PRASHANT GOEL | VP INFORMATION TECHNOLOGY | 35.00 |
Highest
|
$293,256 | $15,368 | $308,624 |
| TRACEY SIKORA | VP OF RESEARCH & CLINICAL PROGRAMS | 35.00 |
Highest
|
$194,233 | $24,588 | $218,821 |
| ALEXANDRA MOORE | VP OF DEVELOPMENT | 35.00 |
Highest
|
$254,340 | $12,713 | $267,053 |
| JILL POLLANDER | VP PATIENT SERVICES | 35.00 |
Highest
|
$187,802 | $24,142 | $211,944 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2025 | $34,577,196 | $40,401,111 | $66,900,297 | $-5,823,915 |
| 2024 | $50,676,798 | $43,034,462 | $72,321,740 | $7,642,336 |
| 2023 | $66,397,453 | $52,832,739 | $65,154,464 | $13,564,714 |
| 2022 | $59,872,383 | $48,420,739 | $49,542,120 | $11,451,644 |
| 2021 | $43,188,172 | $57,720,517 | $37,875,246 | $-14,532,345 |
| 2020 | $42,843,360 | $52,712,119 | $52,774,540 | $-9,868,759 |
| 2019 | $52,413,377 | $41,789,694 | $61,751,096 | $10,623,683 |
| 2018 | $47,123,099 | $34,074,818 | $50,838,028 | $13,048,281 |
Compare NATIONAL ORGANIZATION FOR RARE DISORDERS INC with other nonprofits in Massachusetts and across the country.